Afatinib is an anticancer chemotherapeutic compound that has been approved to treat advanced lung cancers such as non-small cell lung cancer (NSCLC) and is in clinical trials as a potential treatment for other advanced solid tumors such as breast cancer and colorectal cancer. Afatinib exerts its anticancer activity through inhibition of EGFR and EGFR2 (HER2/ErbB2). In vivo, afatinib downregulates expression of HER2, increasing apoptosis and decreasing tumor size.

**References**


